Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-mouse PD1 antibodies are research-grade monoclonal antibodies designed to target murine programmed cell death protein 1 (PD-1, CD279). These biologics are primarily used as laboratory tools in preclinical mouse models to study immune checkpoint regulation. By binding to murine PD-1, these antibodies typically block its interaction with ligands PD-L1 and PD-L2, thereby preventing the suppression of T-cell activity and enhancing anti-tumor immune responses in syngeneic mouse models. They are widely utilized in oncology research (e.g., melanoma, colon carcinoma) and inflammatory disease studies. These reagents are strictly for research use only (RUO) and are not approved for clinical use in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-mouse PD1 antibody.